CD8A and neoplasm: These licensed APCs then cross-present tumor antigens on MHC I to naive CD8+ T cells—providing antigen, co-stimulation and cytokine signals—that drive their differentiation into cytotoxic T lymphocytes capable of directly killing tumor cells [49].